Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome was a weighted score, but individual components of the outcome showed a difference favouring H-ISDN for all-cause mortality, first HHF, and change in quality of life score.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [79]
In the citing paper
“Digoxin may reduce the risk of HF hospitalization in patients with HFrEF treated with ACE-Is, irrespective of diabetes status.519”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [519]
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Self-citationSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Cited by
Items 201–300 of 1,001
Protogerou, A. D., Papaioannou, T. G., Blacher, J., Papamichael, C. M., Lekakis, J. P., & Safar, M. E. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280114f23 · Cited by 108
Anker, S. D., Schroeder, S., Atar, D., Bax, J. J., Ceconi, C., Cowie, M. R., Crisp, A., Dominjon, F., Ford, I., Ghofrani, H.-A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.516 · Cited by 97
Heart Failure in African Americans
Yancy, C. W. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.028 · Cited by 112
Self-citationHuang, Z. M., Gao, E., Fonseca, F. V., Hayashi, H., Shang, X., Hoffman, N. E., Chuprun, J. K., Tian, X., Tilley, D. G., Madesh, M., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004225 · Cited by 113
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure
Emdin, M., Aimo, A., Castiglione, V., Vergaro, G., Georgiopoulos, G. A., Saccaro, L. F., Lombardi, C., Passino, C., Cerbai, E., Metra, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.031 · Cited by 112
Signaling cascades in the failing heart and emerging therapeutic strategies
He, X., Du, T., Long, T., Liao, X., Dong, Y., & Huang, Z. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00972-6 · Cited by 113
“There is also evidence that the combination of hydralazine and isosorbide dinitrate still provides benefits in black patients, in addition to standard chronic heart failure treatment.(342) However, tolerance and resistance are the major shortcomings.”
BackgroundQuality of Care of and Outcomes for African Americans Hospitalized With Heart Failure
Yancy, C. W., Abraham, W. T., Albert, N. M., Clare, R. M., Stough, W. G., Gheorghiade, M., Greenberg, B., O’Connor, C. M., She, L., Sun, J. L., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.028 · Cited by 110
“Given a higher cardiovascular risk profile as measured by everal clinical variables, including a lower mean LVEF, Figure 3 Outcomes in Patients With Left Ventricular Systolic Dysfunction (A) In-hospital outcomes in heart failure patients with left ventricular systolic dysfunction (LVSD) by race.”
BackgroundMethodSelf-citationHeart Failure in Sub-Saharan Africa: Time for Action
Damasceno, A. A. M., Cotter, G., Dzudié, A., Sliwa, K. S., & Mayosi, B. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.030 · Cited by 106
“Some studies have suggested, however, that African-American patients may have a less active renin-angiotensin system and a lower bioavailability of nitric oxide than Caucasians, which would justify a better response to a combination of isosorbide dinitrate/hydralazine than ACE inhibitors ( 33 ).Forinstance,theA-HeFT(A…”
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis
Cleland, J. G. F., Carubelli, V., Castiello, T., Yassin, A., Pellicori, P., & Antony, R. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9306-2 · Cited by 111
Yancy, C. W., Fonarow, G. C., Albert, N. M., Curtis, A. B., Stough, W. G., Gheorghiade, M., Heywood, J. T., McBride, M. L., Mehra, M. R., O’Connor, C. M., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2008.12.016 · Cited by 104
Self-citationPositive effects of nitric oxide on left ventricular function in humans
Rassaf, T. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl096 · Cited by 103
“Recently, it has been shown that isosorbide dinitrate with hydralazine in addition to the standard therapy provides additional benefit in blacks with advanced heart failure.(28) In the present study, we only examined healthy subjects.”
BackgroundI Diretriz Latino-Americana para o Diagnóstico e Tratamento da Cardiopatia Chagásica
Castro, I., de Andrade, J. P., de Paola, Â. A. V., Vilas‐Boas, F., de Oliveira, G. M. M., Marin‐Neto, J. A., Chagas, A. C. P., Rocha, E. A. V., de Oliveira, G. M. M., Zimerman, L. I., et al. (2011) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2011001600001 · Cited by 106
The Standardization of Race and Ethnicity in Biomedical Science Editorials and UK Biobanks
Smart, A., Tutton, R., Martin, P., Ellison, G. T. H., & Ashcroft, R. (2008) · Social Studies of Science · doi:10.1177/0306312707083759 · Cited by 102
Pharmacogenetics and geographical ancestry: implications for drug development and global health
Daar, A. S., & SINGER, P. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1559 · Cited by 103
“, the results of this double-blind, randomized clinical trial were so impressive that in July 2004 the trial (which was endorsed by the Association of Black Cardiologists) had to be stopped for ethical reasons; there was a significantly higher mortality rate in the placebo group than in the group given BiDi”
ResultMünzel, T. F., Steven, S., & Daiber, A. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.09.002 · Cited by 105
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
BiDil: Race Medicine Or Race Marketing?
Sankar, P. L., & Kahn, J. (2005) · Health Affairs · doi:10.1377/hlthaff.w5.455 · Cited by 101
“A-HeFT was designed to enroll just over 1,000 subjects, all African American, all with New York Heart Association class III or IV heart failure.(12) Subjects reB i D i l”
MethodMore answers to the still unresolved question of nitrate tolerance
Münzel, T., Daiber, A., & Gori, T. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht249 · Cited by 100
Sliwa, K. S., & Mayosi, B. M. (2013) · Heart · doi:10.1136/heartjnl-2013-303592 · Cited by 98
Doshi, D., Ben‐Yehuda, O., Bonafede, M., Josephy, N., Karmpaliotis, D., Parikh, M. A., Moses, J. W., Stone, G. W., Leon, M. B., Schwartz, A. J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.060 · Cited by 99
“The estimated prevalence of CAD in patients with HF ranges from 50% to 65% (9,10).”
BackgroundOelze, M. W., Knorr, M., Kröller‐Schön, S., Kossmann, S., Gottschlich, A., Rümmler, R., Schuff, A., Daub, S., Doppler, C. E. J., Kleinert, H., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs100 · Cited by 106
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Antihypertensive Agents in Hemodialysis Patients: A Current Perspective
Inrig, J. K. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2009.00697.x · Cited by 97
Benziger, C. P., do Carmo, G. A. L., & Ribeiro, A. L. P. (2016) · Cardiology Clinics · doi:10.1016/j.ccl.2016.08.013 · Cited by 115
Murali, S., & Baldisseri, M. R. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000183500.47273.8e · Cited by 93
Rhythm Control in Heart Failure Patients With Atrial Fibrillation
Trulock, K. M., Narayan, S. M., & Piccini, J. P. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1169 · Cited by 97
“Studies include SOLVD (Studies of Left Ventricular Dysfunction) (25); SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) (102); DEFINITE (Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation) (103); CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality) (104); I-PRESERVE (Irbesart…”
BackgroundHealth Disparities, Clinical Trials, and the Digital Divide
Adedinsewo, D. A., Eberly, L. A., Sokumbi, O., Rodriguez, J. A., Patten, C. A., & Brewer, L. C. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.05.003 · Cited by 101
Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure
McNamara, D. M., Tam, S. W., Sabolinski, M. L., Tobelmann, P., Janosko, K. M., Taylor, A. L., Cohn, J. N., Feldman, A. M., & Worcel, M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.030 · Cited by 94
Self-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Echocardiography in Translational Research: Of Mice and Men
Scherrer‐Crosbie, M., & Thibault, H. (2008) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.07.001 · Cited by 90
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Cole, R. T., Kalogeropoulos, A. P., Georgiopoulou, V. V., Gheorghiade, M., Quyyumi, A. A., Yancy, C. W., & Butler, J. (2011) · Circulation · doi:10.1161/circulationaha.110.012781 · Cited by 88
Self-citationHeart failure in African Americans: Disparities can be overcome
Sharma, A. K., Colvin, M. M., & Yancy, C. W. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13045 · Cited by 95
Self-citationMedication Dosing for Heart Failure with Reduced Ejection Fraction — Opportunities and Challenges
Marti, C. N., Fonarow, G. C., Anker, S. D., Yancy, C. W., Vaduganathan, M., Greene, S. J., Ahmed, A., Januzzi, J. L., Gheorghiade, M., Filippatos, G. S., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1351 · Cited by 90
Self-citationImplications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
Newman, J. D., O’Meara, E., Böhm, M., Savarese, G., Kelly, P. R., Vardeny, O., Allen, L. A., Lancellotti, P., Gottlieb, S. S., Samad, Z. Z., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.033 · Cited by 96
Mongirdienė, A., Skrodenis, L., Varoneckaitė, L., Mierkytė, G., & Gerulis, J. (2022) · Biomedicines · doi:10.3390/biomedicines10030602 · Cited by 90
Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure
Lopatin, Y. M., Rosano, G. M. C., Fragasso, G., Lopaschuk, G. D., Seferovic, P. M., Gowdak, L. H. W., Vinereanu, D., Abdelhamid, M., Patrick Jourdain, M., & Ponikowski, P. P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.060 · Cited by 87
Contemporary pharmacological treatment and management of heart failure
Bozkurt, B. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-00997-0 · Cited by 93
“Hydralazine and nitrates are indicated in Black patients with HFrEF and NYHA class III–IV symptoms 6,79 .”
Weiner, R. B., Baggish, A. L., Chen-Tournoux, A., Marshall, J. E., Gaggin, H. K., Bhardwaj, A., Mohammed, A. A., Rehman, S. U., Barajas, L., Barajas, J., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs180 · Cited by 84
Ventricular Assist Devices: Important Information for Patients and Families
Givertz, M. M. (2011) · Circulation · doi:10.1161/circulationaha.111.018226 · Cited by 103
Cardiac contractility modulation: a novel approach for the treatment of heart failure
ABI‐SAMRA, F. M., & Gutterman, D. D. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9571-6 · Cited by 90
The Oxidative Stress Concept of Nitrate Tolerance and the Antioxidant Properties of Hydralazine
Daiber, A., Mülsch, A., Hink, U., Mollnau, H., Warnholtz, A., Oelze, M. W., & Münzel, T. F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.030 · Cited by 88
2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure
Heidenreich, P. A., Fonarow, G. C., Breathett, K. K., Jurgens, C. Y., Pisani, B., Pozehl, B., Spertus, J. A., Taylor, K. G., Thibodeau, J. T., Yancy, C. W., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.023 · Cited by 86
“The combination of hydralazine and isosorbide dinitrate is recommended to reduce morbidity and mortality for patients self-described as African Americans with NYHA class III-IV HFrEF receiving optimal therapy with ACE inhibitors and beta blockers, unless contraindicated (78,79).”
BackgroundSelf-citationMcNamara, D. M., Tam, S. W., Sabolinski, M. L., Tobelmann, P., Janosko, K. M., Venkitachalam, L., Ofili, E., Yancy, C. W., Feldman, A. M., Ghali, J. K., et al. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.10.028 · Cited by 83
Self-citationNediani, C., Raimondi, L., Borchi, E., & Cerbai, E. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3198 · Cited by 88
“population with severe HF of a combination of hydralazine and isosorbide dinitrate (368).”
Medical therapy for chronic heart failure
Krum, H., & Teerlink, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61038-6 · Cited by 86
Side effects of using nitrates to treat angina
Thadani, U., & Rodgers, T. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.5.667 · Cited by 82
“Furthermore, in African-American patients with heart failure, many of whom had underlying coronary artery disease, long-term treatment with high-dose isosorbide dinitrate plus hydralazine reduced mortality compared with placebo therapy [42,43].”
BackgroundCardiorenal Syndrome in Critical Care: The Acute Cardiorenal and Renocardiac Syndromes
Cruz, D. N. (2012) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2012.10.005 · Cited by 89
Towards precision medicine in heart failure
Weldy, C. S., & Ashley, E. A. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00566-9 · Cited by 89
Treatment of hypertension in patients with coronary artery disease
Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., Findeiss, L., et al. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2015.03.002 · Cited by 89
Management of acute decompensated heart failure
Allen, L. A., & O'Connor, C. M. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.051620 · Cited by 93
Exploiting Race in Drug Development
Kahn, J. (2008) · Social Studies of Science · doi:10.1177/0306312708091928 · Cited by 79
HIV Infection and Risk of Cardiovascular Diseases Beyond Coronary Artery Disease
Barnes, R. P., Lacson, J. C. A., & Bahrami, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0652-3 · Cited by 79
Mazurek, J. A., & Jessup, M. L. (2015) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2015.08.001 · Cited by 81
Taylor, A. L., & Wright, J. T. (2005) · Circulation · doi:10.1161/circulationaha.105.540443 · Cited by 79
Self-citationBiDil: Assessing a Race-Based Pharmaceutical
Brody, H., & Hunt, L. M. (2006) · The Annals of Family Medicine · doi:10.1370/afm.582 · Cited by 87
Understanding Nitric Oxide Physiology in the Heart: A Nanomedical Approach
Maliñski, T. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.029 · Cited by 77
Anderson, H. R. (2005) · BMJ · doi:10.1136/bmj.330.7499.1037 · Cited by 77
Skali, H., Dwyer, E. M., Goldstein, R., Haigney, M., Krone, R., Kukin, M., Lichstein, E., McNitt, S., Moss, A. J., Pfeffer, M. A., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.71 · Cited by 76
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure
Kim, M., Lee, J., Kim, E. J., Park, D.-G., Park, S., Park, J. J., Shin, M., Yoo, B., Youn, J., Lee, S. E., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0009 · Cited by 80
The causes, consequences, and treatment of left or right heart failure
Peteiro, J., Peteiro-Vázquez, J., Gacía-Campos, A., García‐Bueno, L., Abugattás-de-Torres, J. P., & Castro‐Beiras, A. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10669 · Cited by 95
How robust are clinical trials in heart failure?
Docherty, K. F., Campbell, R. T., Jhund, P. S., Petrie, M. C., & McMurray, J. J. V. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw427 · Cited by 83
Daiber, A., Andreadou, I., Oelze, M. W., Davidson, S. M., & Hausenloy, D. J. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.12.026 · Cited by 78
Mazurek, J. A., & Jessup, M. L. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2016.07.001 · Cited by 92
Benjamin, E. J., Jessup, M. L., Flack, J. M., Krumholz, H. M., Liu, K., Nadkarni, V., Rhoades, D. A., Rodríguez, B. L., Scott, R. P., Taylor, M. P., et al. (2005) · Circulation · doi:10.1161/01.cir.0000157742.95689.65 · Cited by 75
Self-citationGuideline-Directed Medical Therapy for the Treatment of Heart Failure with Reduced Ejection Fraction
Patel, J., Rassekh, N., Fonarow, G. C., DEEDWANIA, P. C., Sheikh, F. H., Ahmed, A., & Lam, P. H. (2023) · Drugs · doi:10.1007/s40265-023-01887-4 · Cited by 89
“Hydralazine and ISDN attenuate this process and may be considered as supplemental treatment to conventional GDMT in patients with chronic heart failure [50].”
BackgroundImplications of Pharmacogenomics for Drug Development and Clinical Practice
Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S., & Schulman, K. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.20.2331 · Cited by 76
Cohn, J. N., Tam, S. W., Anand, I. S., Taylor, A. L., Sabolinski, M. L., & Worcel, M. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.03.001 · Cited by 77
Self-citationNebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation
Weiss, R. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.303 · Cited by 79
“The importance of NO in black patients has been shown in the treatment of congestive heart failure where a regimen of hydralazine and nitrates reduced mortality by 43% over a standard regimen including an ACE inhibitor and a beta-blocker (Taylor et al 2004).”
A perspective on African American participation in clinical trials
Shaya, F. T., Gbarayor, C. M., Yang, H.-W. K., Agyeman-Duah, M., & Saunders, E. (2006) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.10.001 · Cited by 76
Ix, J. H., Allison, M., Denenberg, J. O., Cushman, M., & Criqui, M. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.022 · Cited by 73
A review of heart failure management in the elderly population
Cheng, J. W. M., & Nayar, M. (2009) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2009.10.001 · Cited by 78
Salt and essential hypertension: pathophysiology and implications for treatment
Garfinkle, M. A. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.04.006 · Cited by 87
“No or negligible changes (2 mmHg) in blood pressure after follow-up were seen (47, 48).”
BackgroundJessup, M. L., Banner, N. R., Brozena, S. C., Campana, C., Costard‐Jäckle, A., Dengler, T. J., Hunt, S. A., Metra, M., Rahmel, A. O., Renlund, D. G., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.06.007 · Cited by 76
Nitric oxide signaling in the cardiovascular system: implications for heart failure
Saraiva, R. M., & Hare, J. M. (2006) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000221584.56372.dc · Cited by 80
The Genetics of Uterine Leiomyomata
Stewart, E. A., & Morton, C. C. (2006) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000206161.84965.0b · Cited by 72
Enfermedad cardiovascular en el anciano
Jackson, C. F., & WENGER, N. K. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.05.001 · Cited by 95
“El tratamiento combinado con hidralazina y dinitrato de isosorbida es una alternativa razonable a los IECA o los ARA-II en los pacientes con insuficiencia renal recurrente o hiperpotasemia durante el empleo de estas medica-ciones, como ocurre con bastante frecuencia en los ancianos.”
BackgroundInfluentialHeart Failure With Preserved Ejection Fraction in African Americans
Gupta, D. K., Shah, A. M., Castagno, D., Takeuchi, M., Loehr, L. R., Fox, E. R., Butler, K. R., Mosley, T. H., Kitzman, D. W., & Solomon, S. D. (2013) · JACC Heart Failure · doi:10.1016/j.jchf.2013.01.003 · Cited by 79
“studies focus specifically on African Americans (23) because most literature involving race in HF addresses differences among racial groups.”
BackgroundAmado, L. C., SALIARIS, A. P., Raju, S., Lehrke, S., John, M. S., XIE, J., Stewart, G. C., Fitton, T. P., Minhas, K. M., BRAWN, J., et al. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.04.008 · Cited by 79
The Impact of Health Care Disparities on Patients With Heart Failure
Morris, A. A., Shah, K., Enciso, J. S., Hsich, E., Ibrahim, N. E., Page, R. L., II, Yancy, C. W., Butler, J., Hsich, E., Pressler, S. J., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.04.008 · Cited by 77
Self-citationDirect Vasodilators and Sympatholytic Agents
McComb, M. N., Chao, J. Y., & Ng, T. M. H. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415587969 · Cited by 75
Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals
Myers, V. D., Gerhard, G. S., McNamara, D. M., Tomar, D., Madesh, M., Kaniper, S., Ramsey, F. V., Fisher, S. G., Ingersoll, R., Kasch-Semenza, L., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2541 · Cited by 73
Self-citationPharmacogenomics: a systems approach
Wang, L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.42 · Cited by 65
Modulation of cGMP in Heart Failure: A New Therapeutic Paradigm
Boerrigter, G., Lapp, H., & Burnett, J. C. J. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-68964-5_21 · Cited by 69
“…a combination of a nitrate (isosorbide dinitrate) and hydralazine demonstrated improved outcomes compared to placebo before the introduction of ACE inhibitors (Cohn et al. 1986) and more recently in African Americans even on top of therapy with ACE inhibitors and beta blockers (Taylor et al. 2004).”
BackgroundOutcomes by Gender in the African-American Heart Failure Trial
Taylor, A. L., Lindenfeld, J., Ziesche, S., Walsh, M. N., Mitchell, J. E., Adams, K. F., Tam, S. W., Ofili, E., Sabolinski, M. L., Worcel, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.020 · Cited by 68
“The primary efficacy end point for the trial was a omposite score weighting all-cause mortality, first hospialization for heart failure, and change in quality of life at months (7).”
BackgroundSelf-citationLearning from failure: congestive heart failure in the postgenomic age
Benjamin, I. J., & Schneider, M. D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524477 · Cited by 72
Current and emerging drug targets in heart failure treatment
Ghionzoli, N., Gentile, F., Franco, A. D., Castiglione, V., Aimo, A., Giannoni, A., Burchielli, S., Cameli, M., Emdin, M., & Vergaro, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10137-2 · Cited by 72
Animal models of insulin resistance and heart failure
Velez, M., Kohli, S., & Sabbah, H. N. (2013) · Heart Failure Reviews · doi:10.1007/s10741-013-9387-6 · Cited by 71
“In studies with larger proportions of African-Americans, the prevalence of T2DM can be as high as 40 % [8, 13].”
Chirinos, J. A., & Zamani, P. (2016) · Current Heart Failure Reports · doi:10.1007/s11897-016-0277-9 · Cited by 67
Zhang, F., & Finkelstein, J. (2019) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s207449 · Cited by 74
Effects of Exercise Training on Outcomes in Women With Heart Failure
Piña, I. L., Bittner, V., Clare, R. M., Swank, A. M., Kao, A. C., Safford, R. E., Nigam, A., Barnard, D. D., Walsh, M. N., Ellis, S. J., et al. (2014) · JACC Heart Failure · doi:10.1016/j.jchf.2013.10.007 · Cited by 76
Predictors of short term mortality in heart failure — Insights from the Euro Heart Failure survey
Velavan, P., Khan, N. K., Goode, K. M., Rigby, A. S., Loh, P. H., Michel Komajda, N., Folláth, F., Swedberg, K. B., Madeira, H. C., & Cleland, J. G. F. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.08.004 · Cited by 65
“A similar association was observed with nitrates, consistent with the outcomes of the V-HeFT-I and A-HeFT trials [14,15].”
ResultMant, J., Al‐Mohammad, A., Swain, S., Laramée, P., & for the Guideline Development Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-4-201108160-00009 · Cited by 72
Wei, S., Le, N., Zhu, J. W., Breathett, K. K., Greene, S. J., Mamas, M. A., Zannad, F. M., & Spall, H. G. C. V. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008685 · Cited by 67
Nitric Oxide Releasing Nanomaterials for Cardiovascular Applications
Tabish, T. A., Crabtree, M. J., Townley, H. E., Winyard, P. G., & Lygate, C. A. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.07.017 · Cited by 81
Hypertension in Cardiovascular and Kidney Disease
Botdorf, J., Chaudhary, K. R., & Whaley‐Connell, A. T. (2011) · Cardiorenal Medicine · doi:10.1159/000329927 · Cited by 71
“Notable reflexive tachycardia is associated with the use of hydralazine that can be controlled with β-blockers or a centrally acting α-agonist. When combined with a nitrate, significant reduction in mortality in Blacks with heart failure was seen, but this has not been specifically studied in the setting of CKD [”
BackgroundMedicating race: heart disease and durable preoccupations with difference
Pollock, A. (2013) · Choice Reviews Online · doi:10.5860/choice.50-5029 · Cited by 64
Anand, I. S., Tam, S. W., Rector, T. S., Taylor, A. L., Sabolinski, M. L., Archambault, W. T., Adams, K. F., Olukotun, A. Y., Worcel, M., & Cohn, J. N. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.109 · Cited by 63
Self-citationClinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure
Guazzi, M. (2008) · Circulation Heart Failure · doi:10.1161/circheartfailure.108.802116 · Cited by 64
Assessing quality-of-life outcomes in cardiovascular clinical research
Mark, D. B. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.10 · Cited by 68
Metadata
- Authors
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N.
- Affiliations
- University of Minnesota (US)
- United States Department of Veterans Affairs (US)
- The University of Texas Southwestern Medical Center (US)
- Veterans Health Administration (US)
- Xavier University of Louisiana (US)
- Association of Black Cardiologists (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2049-2057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140023412
- Cited by
- 1,773
- References
- 61
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 43 · 2023: 67 · 2022: 68 · 2021: 70 · 2020: 76 · 2019: 53 · 2018: 58 · 2017: 90 · 2016: 78 · 2015: 79 · 2014: 76 · 2013: 78 · 2012: 97
- FWCI
- 84.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- isosorbide dinitrate, hydralazine, advanced heart failure, Black patients, fixed-dose combination, mortality, heart failure hospitalization, quality of life, dilated ventricles
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Quality of Life, Vasodilator Agents, Survival Analysis, Treatment Outcome, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.